SCHEMBL13725635

SCHEMBL13725635

OB(O)c1c2ccccc2c(-c2ccc3ccc4cccc5ccc2c3c45)c2ccccc12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 5/20 0.43
ERBB2 P04626 1/20 0.43
FYN P06241 1/20 0.43
MAOA P21397 1/20 0.43
ACHE P22303 1/20 0.43
AHR P35869 1/20 0.43
ALDH1A1 P00352 6/20 0.42
HPGD P15428 6/20 0.42
HSD17B10 Q99714 4/20 0.42
THRB P10828 1/20 0.42
CYP3A4 P08684 2/20 0.38
TSHR P16473 2/20 0.38
TDP1 Q9NUW8 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
CYP1A1 P04798 1/20 0.35
CYP1B1 Q16678 1/20 0.35
PPARG P37231 2/20 0.35
RXRA P19793 1/20 0.35
PPARD Q03181 1/20 0.35
PPARA Q07869 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3284115 0.81 CYP1A2 (0.47) CYP1A2ERBB2FYNMAOAACHE
SCHEMBL17491086 0.81 CRHBP (0.44) CYP1A2ALDH1A1HPGDHSD17B10CYP3A4
SCHEMBL971636 0.81 DHFR (0.40) CYP1A2ALDH1A1HSD17B10TSHRTDP1
SCHEMBL29464271 0.81 DHFR (0.40) CYP1A2ALDH1A1HSD17B10TSHRTDP1
SCHEMBL1816279 0.80 ALDH1A1 (0.54) CYP1A2ERBB2FYNMAOAACHE
SCHEMBL996762 0.80 CYP1A2 (0.53) CYP1A2ERBB2FYNMAOAACHE
SCHEMBL18566632 0.79 CYP1A2 (0.44) CYP1A2ERBB2FYNMAOAACHE
SCHEMBL13674293 0.78 CYP1A2 (0.47) CYP1A2ERBB2FYNMAOAACHE
SCHEMBL28682862 0.78 CYP1A2 (0.66) CYP1A2ERBB2FYNMAOAACHE
SCHEMBL24605123 0.77 CYP1A2 (0.46) CYP1A2ERBB2FYNMAOAACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090200929-A1 ANTHRACENE DERIVATIVE AND ORGANIC ELECTROLUMINESCENCE DEVICE EMPLOYING THE SAME IDEMITSU KOSAN CO. LTD. (JP) 2009-08-13 US disclosed
US-20090200929-A1 ANTHRACENE DERIVATIVE AND ORGANIC ELECTROLUMINESCENCE DEVICE EMPLOYING THE SAME IDEMITSU KOSAN CO. LTD. (JP) 2009-08-13 US disclosed
US-7504526-B2 Anthracene derivative and organic electroluminescence device employing the same IDEMITSU KOSAN CO., LTD. (JP) 2009-03-17 US disclosed
US-7504526-B2 Anthracene derivative and organic electroluminescence device employing the same IDEMITSU KOSAN CO., LTD. (JP) 2009-03-17 US disclosed
EP-1754696-A1 ANTHRACENE DERIVATIVE AND ORGANIC ELECTROLUMINESCENT DEVICE USING SAME IDEMITSU KOSAN CO., LTD. (JP) 2007-02-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090200929-A1 ANTHRACENE DERIVATIVE AND ORGANIC ELECTROLUMINESCENCE DEVICE EMPLOYING THE SAME ALKBH2, ANXA7, ANXA2 CYP1A2 97/4885ERBB2 3550/4885FYN 3988/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.